(NASDAQ: NPCE) Neuropace's forecast annual revenue growth rate of 16.06% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.09%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Neuropace's revenue in 2024 is $65,421,000.On average, 3 Wall Street analysts forecast NPCE's revenue for 2024 to be $2,145,745,710, with the lowest NPCE revenue forecast at $2,126,414,668, and the highest NPCE revenue forecast at $2,164,963,374. On average, 3 Wall Street analysts forecast NPCE's revenue for 2025 to be $2,480,722,630, with the lowest NPCE revenue forecast at $2,413,545,841, and the highest NPCE revenue forecast at $2,531,459,530.
In 2026, NPCE is forecast to generate $2,915,160,882 in revenue, with the lowest revenue forecast at $2,656,232,623 and the highest revenue forecast at $3,117,059,731.